Latest ebit for ISCNF: $-4.5M, below the sector sector average of $2.4T.
Get informed when a big investor buys or sells
+ FollowAs of Aug 31, 2022
Trailing 12 months ending Aug 31, 2022
As of the most recent data (August 2022), ISCNF shows a EBIT of $-4.5M. That compares with $-24M in the prior-year period — up 81.4% year over year. That is below the sector sector average of $2.4T. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, ISCNF's EBIT is now $-4.5M (was $-24M) — a 81.4% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Isracann Biosciences is outperforming or lagging.
The its sector sector average EBIT is about $2.4T. Isracann Biosciences is at $-4.5M, which is lower that average. That is roughly 100.0% below the sector mean. Use the comparison chart on this page to see how ISCNF stacks up against individual peers as well.
Tracking ISCNF's ebit over time shows whether Isracann Biosciences is scaling, shrinking, or reshaping that part of the business. The current reading is $-4.5M That compares with $-24M in the prior-year period — up 81.4% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this ebit page, Stockcircle has Isracann Biosciences's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect EBIT (currently $-4.5M) with ownership activity and broader fundamentals.